Spedding Research Solutions

Spedding Research Solutions operates a hybrid business model, combining fee-for-service CRO work in drug formulation and analytics with its own proprietary drug discovery programs. Its most advanced asset is a Phase 2-ready compound with orphan drug designation for ALS (Amyotrophic Lateral Sclerosis), derived from a novel pathway discovery. The company leverages the scientific reputation of its founder, Michael Spedding—a highly cited pharmacologist and Secretary-General of IUPHAR—to organize research consortia and pursue grants, positioning itself at the intersection of service provision and early-stage therapeutic development.

A hybrid model combining contract research organization (CRO) services in formulation/analytics with a consortium-based research platform focused on applying deep pharmacological principles and lateral thinking to identify novel pathways and repurpose insights across diseases (e.g., from ALS to COVID-19).

In CRO services, it competes with numerous small to large firms on expertise and cost. In drug discovery, its niche is its unique scientific approach and consortium model, rather than direct competition with large biotechs. Its ALS program enters a competitive neurodegenerative space with high failure rates, where success depends on differentiated science and efficient trial design.